#clvs

(clvs)

(clvs)

(clvs)

Albireo Pharma (ALBO:NAS) Fundamental Valuation Report

Fundamental Valuation Report Albireo Pharma(ALBO:NAS) Healthcare:Biotechnology This Report was generated using the valuation tools available on StockCalc.com. For a free 30 day trial click here. –Close Price/Date$32.92 (USD) 04/15/2021 Weighted Valuation$31.89 (USD) Overall RatingFairly valued to slightly Overvalued by 3.1% Valuation Models Adjusted Book Value: $27.17…

Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot

— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.

— Product revenues grew by 30% to $39.3 million versus $38.97 million expected. The top line benefited from the US net product revenue.

— The supply of free drugs distributed to eligible patients in the U.S. through the Rubraca patient assistance program for Q4…

Affaire Collège-Lycée Victor Schoelcher : Menaces aux rédactions locales et autres, le rectorat réagit

Certains d’entre vous se rappellerons probablement du feuilleton judiciaire Collège-Lycée Victor Schoelcher entre la famille Héritier et la S.A.R.L. EPONINE qui à fait quelques unes de la presse locale de Saint-Martin

Pour autant, nous concernant, nous n’avons jamais réellement développé les différents rebondissements du sujet Ecole Frenet, Collège Victor Schoelcher. Ce matin, nous avons reçu,…

Clovis Oncology dips further as loss widens in Q2

Clovis Oncology (NASDAQ: CLVS) on Thursday reported second quarter results that were weaker than the street expectations.  Total revenues rose 39% year-over-year to $32.98 million, vs. the Wall Street estimate of $34.92 million.

Q2 loss of $2.27 per share was wider than $1,94 per shre it posted last year, and worse than the analysts’ estimate of $1.71 per share loss.

CLVS shares plunged…